[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Tsinghua Chang Gung Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":633},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,45,79,101,127,154,179,208,233,255,279,301,320,351,374,395,414,432,456,477,506,533,558,581,607],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100583797","biliary-dilatation-national-special-disease-cohort-in-china-100583797",false,"NCT06881004","Biliary Dilatation National Special Disease Cohort in China","Establishment and Evaluation of Clinical Classification and Surgical Decision-making System for Biliary Dilatation：a National Special Disease Cohort Study in China","Inclusion Criteria:\n\n1. Patients who have been definitive diagnosed with biliary dilation.\n2. Patients aged between 0 and 80 years old, regardless of gender.\n3. In line with the principle of informed consent: For the retrospective cohort of biliary dilation, exemption from signing the informed consent form is applied for, while for the prospective cohort, signing the informed consent form is required.\n\nExclusion Criteria:\n\n* None","ALL","80 Years",{"count":20,"type":21},6000,"ESTIMATED","OBSERVATIONAL","This study is a multicenter, bidirectional cohort study aimed at continuously enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for bile duct dilatation. Based on this cohort, the study seeks to clarify the epidemiological characteristics, pathological features, standard classification, disease progression, cancer risk, and optimal timing for surgical intervention in patients with bile duct dilatation. Additionally, it will compare the perioperative risks, long-term outcomes, and quality of life among different types of patients (including Todani types I, IVa, and V) following surgical treatment, to establish standardized surgical treatment strategies for each type.",[25],"Choledochal Cyst",[27,28,29,30,31],"Biliary dilatation","Cohort study","Clinical database","Surgical treatment","Long-term outcome","RECRUITING","2026-06-22",{"date":35,"type":36},"2026-06-23","ACTUAL",{"date":38,"type":36},"2025-03-19",{"date":40,"type":21},"2035-03-31",{"name":42,"class":43},"Beijing Tsinghua Chang Gung Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100618701","prediction-model-for-mins-after-major-hepatobiliary-surgery-100618701","NCT07335042","Prediction Model for MINS After Major Hepatobiliary Surgery","Development of an Interpretable Prediction Model for Myocardial Injury After Noncardiac Surgery in Patients Undergoing Major Hepatobiliary Surgery","Inclusion Criteria:\n\nAdults (18-85 yr, ASA physical status II-III) undergoing major hepatobiliary surgery were enrolled. Major surgery was defined as duration ≥ 3 h involving hepatectomy (≥ 3 segments) or biliary reconstruction necessitating ICU admission. Eligibility required paired perioperative high-sensitivity cardiac troponin T (hs-cTnT) data and comprehensive documentation of surgical covariates, including surgical approach (laparoscopic vs. open), resection nature (anatomic vs. non-anatomic), number of resected segments, tumor characteristics (size and location), and presence of cirrhosis.\n\nExclusion Criteria:\n\n(1) preoperative acute myocardial infarction, unstable angina, heart failure, or chronic kidney disease (estimated glomerular filtration rate \\\u003C 60 ml\u002F (min · 1.73 m2); (2) undocumented inflow occlusion strategy; or (3) non-imputable missing covariates.","18 Years","85 Years",{"count":55,"type":21},1800,"This multi-center, prospective observational study aims to develop and validate an interpretable prediction model for Myocardial Injury After Noncardiac Surgery (MINS) in patients undergoing major hepatobiliary surgery. The study adopts a nested modeling strategy, starting with baseline risk factors (e.g., RCRI) and stepwise incorporating hepatic inflow occlusion strategies (specifically comparing SPVO vs. Pringle maneuver) and routine intraoperative biomarkers. The model's performance will be evaluated using AUC, Net Reclassification Improvement (NRI), and Decision Curve Analysis (DCA), followed by interpretability analysis using SHAP values and external validation in an independent cohort.",[58,59,60,61],"Myocardial Injury After Noncardiac Surgery (MINS)","Postoperative Complications","Liver Neoplasm","Hepatobiliary Diseases",[63,64,65,66,67,68,69],"MINS","Major Hepatobiliary Surgery","Hepatectomy","Hepatic Inflow Occlusion","Pringle Maneuver","Prediction Model","High-sensitivity Cardiac Troponin","2026-06-12",{"date":72,"type":36},"2026-06-15",{"date":74,"type":36},"2026-01-14",{"date":76,"type":21},"2027-06-30",{"name":42,"class":43},6,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":44},"100618334","ptc-guided-therapy-for-peritoneal-mesothelioma-100618334","NCT07330271","PTC-Guided Therapy for Peritoneal Mesothelioma","A Multicenter, Randomized Controlled Trial of PTC-Guided Personalized Therapy for Peritoneal Mesothelioma","Inclusion Criteria:\n\nPatients must meet ALL of the following criteria to be eligible for the study:\n\n* Aged 18 years or older.\n* Histopathologically confirmed diagnosis of epithelioid or biphasic malignant peritoneal mesothelioma (MPM).\n* Scheduled to undergo cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and subsequent adjuvant therapy.\n* Availability of sufficient fresh tumor tissue sample obtained during surgery for Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.\n* Karnofsky Performance Status (KPS) score \\> 60.\n* Adequate hematologic function:\n* White blood cell count ≥ 3.5 × 10⁹\u002FL\n* Platelet count ≥ 80 × 10⁹\u002FL\n* Adequate hepatic function:\n* Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) \\\u003C 2 × upper limit of normal (ULN)\n* Adequate renal function:\n* Serum creatinine \\\u003C 1.2 × ULN\n* Adequate cardiac and pulmonary function to tolerate major surgery, as assessed by the investigator.\n* Voluntarily agrees to participate by providing written informed consent and demonstrates good compliance.\n\nExclusion Criteria:\n\nPatients who meet ANY of the following criteria will be excluded from the study:\n\n* Presence of concurrent severe medical comorbidities that, in the investigator's judgment, preclude tolerance to the study treatment.\n* Diagnosis of another active malignant tumor during the screening process, which may interfere with the study outcomes.\n* Considered by the investigator to be unsuitable for participation in this study for any other reason (e.g., psychological, familial, or social factors).\n* Unwillingness to accept the assigned treatment regimen or the required follow-up schedule.",{"count":87,"type":21},347,"INTERVENTIONAL",[90],"NA","Official Title: A Study of Key Parameters and Mechanisms in Personalized Diagnosis and Treatment Using Tumor Models\n\nWhy is this study being done? This research study is for adults with a type of cancer called Malignant Peritoneal Mesothelioma (MPM). Currently, it is hard for doctors to know which treatment will work best for each patient after surgery. This study will test a new, personalized way to choose treatments using a model grown from a patient's own tumor in the lab, called a Patient-derived tumor-like cell cluster (PTC) model. The main goal is to see if using this PTC model to guide treatment can help patients live longer without their cancer getting worse, compared to a standard chemotherapy treatment.\n\nWho can participate? Adults aged 18 and older with a specific type of MPM (epithelioid or biphasic) who are planned to have surgery and heated chemotherapy (CRS+HIPEC) and can provide a tumor sample for the PTC model may be eligible.\n\nWhat will happen in the study?\n\n* Participants will be randomly assigned to one of two groups by chance, like flipping a coin.\n* Standard Treatment Group: This group will receive the standard chemotherapy combination of Gemcitabine, Oxaliplatin, and Apatinib. Additionally, if the patient's tumor tests positive for PD-L1 (≥1%), the immunotherapy drug Sintilimab will be given together with the chemotherapy.\n* Personalized Treatment Group: This group will have a PTC model made from their tumor. The model will be tested with different drugs (chemotherapy, targeted therapy, and immunotherapy) in the lab. The treatment that works best on the model will be chosen for the patient.\n* Both groups will receive their assigned treatment for 6 cycles.\n* Participants will be followed for several years to see how they are doing, through clinic visits and scans.\n\nWhat are the possible benefits? Participants in the personalized treatment group might receive a therapy that is more effective for their specific cancer. The information from this study may help doctors better treat future patients with MPM.\n\nWhat are the possible risks? The risks include side effects from cancer treatments, which can include low blood cell counts, nausea, vomiting, high blood pressure, liver problems, and tiredness. There is also a risk that the PTC model may not grow successfully in the lab, or that the drug that works in the model may not work as well in the body. The study team will closely monitor all participants for any side effects and manage them promptly.\n\nWho is paying for the study? This study is funded by the National Key R\\&D Program of China.\n\nWhere is the study taking place? The study is conducted at multiple hospitals in China, including Beijing Tsinghua Changgung Hospital, Beijing Shijitan Hospital, and Cangzhou Central Hospital, and Shijiazhuang People's Hospital.",[93],"Peritoneal Mesothelioma","2026-06-11",{"date":72,"type":36},{"date":97,"type":36},"2025-12-02",{"date":99,"type":21},"2031-11-01",{"name":42,"class":43},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":88,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100639296","multicenter-clinical-study-on-robotic-assisted-surgical-management-of-posterior-cruciate-ligament-tibial-avulsion-fractures-100639296","NCT07575256","Multicenter Clinical Study on Robotic-Assisted Surgical Management of Posterior Cruciate Ligament Tibial Avulsion Fractures","Inclusion Criteria:\n\n* Age ≥ 18 years\n\n  * Acute closed tibial avulsion fracture, with surgery performed within 3 weeks of injury ③ Radiographically confirmed Meyers-McKeever classification Type II or III fracture ④ Absence of absolute contraindications to surgical intervention ⑤ Provision of voluntary, written informed consent prior to enrollment\n\nExclusion Criteria:\n\n* Pathological fractures or complex ipsilateral injuries, including concomitant fractures at other anatomical sites.\n\n  * Prior ipsilateral knee joint surgery. ③. Significant vascular or neurological compromise.\n\n    * Acute meniscal tears, acute anterior cruciate ligament (ACL) ruptures, or acute injuries to the medial or lateral collateral ligaments.\n\n      * Compromised local soft tissue integrity, including open fractures. ⑥. Withdrawal from the study or loss to follow-up despite having provided written informed consent.",{"count":108,"type":21},22,[90],"The primary objective of this clinical trial is to evaluate the efficacy of robotic-assisted surgery in the management of posterior cruciate ligament (PCL) avulsion fractures involving the tibial insertion site of the cruciate ligament. Specifically, the study seeks to determine: (1) whether robotic-assisted surgery yields superior anatomical reduction accuracy-particularly in restoring the native position of the tibial avulsion fragment-compared with conventional open reduction and internal fixation (ORIF); and (2) whether such improved precision translates into enhanced long-term functional recovery of the knee joint.",[112,113,114],"PCL - Posterior Cruciate Ligament Deficiency","Posterior Cruciate Ligament Tear","PCL - Posterior Cruciate Ligament Rupture",[116,117],"Posterior Cruciate Ligament tibial avulsion fractures","Robot-assisted surgery","NOT_YET_RECRUITING","2026-05-04",{"date":121,"type":36},"2026-05-08",{"date":123,"type":21},"2026-05-10",{"date":125,"type":21},"2030-12-31",{"name":42,"class":43},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100636023","3d-eit-for-diagnosis-and-monitoring-of-pulmonary-embolism-100636023","NCT07560293","3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism","Prospective Validation of Three-Dimensional Electrical Impedance Tomography for the Diagnosis, Risk Stratification, and Longitudinal Monitoring of Pulmonary Embolism","TIDE-PE","Inclusion Criteria:\n\n* Age 18 years or older\n* Body mass index (BMI) less than 50 kg\u002Fm²\n* Able to provide written informed consent\n* first episode of pulmonary embolism confirmed by CT pulmonary angiography (CTPA), with or without CT venography (CTV)\n\nExclusion Criteria:\n\n* Previous diagnosis of pulmonary embolism\n* Pregnancy\n* Thoracic deformity or chest wall abnormality preventing proper placement of the EIT electrode belt\n* Contraindications to EIT use, including implantable cardioverter-defibrillator, pacemaker, implanted pumps, or chest wounds limiting electrode placement\n* Concurrent participation in another interventional clinical study Hemodynamic instability requiring emergency intervention that precludes completion of the EIT examination (PE cohort only)\n* Any other condition judged by the investigator to make the participant unsuitable for study participation",{"count":136,"type":21},115,"This prospective observational study aims to validate three-dimensional electrical impedance tomography (3D-EIT) as a non-invasive bedside tool for the diagnosis and longitudinal monitoring of pulmonary embolism (PE). The study will include a PE cohort and a control cohort without PE or venous thromboembolism (VTE). Using algorithms that separate ventilation and perfusion signals, 3D-EIT-derived indices, including the Matching Index (MI), Dead Space Index (DI), and Shunt Index (SI), will be quantified. The diagnostic performance of MI and DI will be evaluated against computed tomography pulmonary angiography (CTPA), and their associations with PE severity, risk stratification, and treatment response will be explored. This study is expected to support the clinical translation of 3D-EIT as a radiation-free bedside functional imaging tool for PE management.",[139,140],"Pulmonary Embolism (Diagnosis)","Venous Thromboembolism (VTE)",[142,143,144,145,146],"Pulmonary Embolism","Electrical Impedance Tomography","Three-dimensional Imaging","Lung Perfusion","Ventilation-Perfusion Mismatch","2026-04-24",{"date":149,"type":36},"2026-05-01",{"date":149,"type":21},{"date":152,"type":21},"2028-05-01",{"name":42,"class":43},{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":44},"100634376","ai-assisted-staging-and-treatment-decision-making-for-hepatocellular-carcinoma-100634376","NCT07538882","AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma","A Prospective, Randomized, Controlled, Crossover Study of Artificial Intelligence-Assisted Multi-Dimensional Staging and Treatment Decision-Making for Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Age \\>= 18 years.\n* Patients prospectively presenting with suspected or newly diagnosed primary hepatocellular carcinoma (HCC) later confirmed by pathology or meeting the China Liver Cancer (CNLC) guidelines.\n* Complete baseline clinical data acquired during the prospective enrollment period, including complete history of present\u002Fpast illness, ECOG PS score, comprehensive laboratory tests (liver function, coagulation, tumor markers such as AFP, etc.), and baseline abdominal contrast-enhanced CT.\n* Patients (or their legal representatives) must provide written informed consent for their clinical data to be used in this trial.\n\nExclusion Criteria:\n\n* Patients with secondary (metastatic) liver cancer or concurrent severe malignancies of other systems.\n* Patients who fail to complete the required baseline imaging or laboratory tests, preventing accurate staging calculation (e.g., missing data for Child-Pugh score).\n* Patients who have previously received anti-tumor therapies for liver cancer prior to enrollment.",{"count":162,"type":21},108,"The precise treatment of primary hepatocellular carcinoma (HCC) highly depends on accurate disease staging (CNLC, TNM, BCLC) and scientific treatment decision-making, which necessitate the integration of both imaging and clinical baseline data. This study prospectively recruits HCC patients and clinical physicians across different hospital tiers to evaluate the clinical value of a self-developed artificial intelligence (AI) model in assisting multi-dimensional comprehensive assessment and treatment decision-making. Utilizing a Multi-Rater Multi-Case (MRMC) crossover balanced design, the study compares the accuracy of clinical evaluations performed by physicians under \"unassisted (without AI)\" versus \"AI-assisted\" conditions. A key focus is to explore whether AI can significantly enhance the comprehensive assessment capabilities of physicians in primary\u002Fsecondary care hospitals, thereby prospectively reducing diagnostic and therapeutic heterogeneity across different institutional levels.",[165],"Hepatocellular Carcinoma (HCC)",[167,168,169,170,171],"Hepatocellular Carcinoma","Artificial Intelligence","Staging","Clinical Decision-Making","Diagnostic Accuracy","2026-04-13",{"date":174,"type":36},"2026-04-20",{"date":172,"type":21},{"date":177,"type":21},"2026-05-20",{"name":42,"class":43},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":187,"targetDuration":4,"studyType":88,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},"100602451","ai-assisted-blood-pressure-control-during-anesthesia-100602451","NCT07123675","AI-Assisted Blood Pressure Control During Anesthesia","A Dual-Center, Randomized, Controlled, Proof-of-Concept Trial to Evaluate an AI-Based Decision Support System for Intraoperative Blood Pressure Management","RL-PRAIS PoC","Inclusion Criteria:\n\n* Age 18 to 85 years\n* Scheduled for elective non-cardiac surgery\n* Receiving intravenous-inhalation combined general anesthesia with tracheal intubation\n* ASA physical status I to IV\n* Anesthesia maintenance plan includes propofol for continuous sedation, remifentanil for continuous analgesia, and sevoflurane or desflurane for inhalation anesthesia\n* Continuous invasive arterial blood pressure monitoring during surgery\n* Continuous monitoring of heart rate and Bispectral Index (BIS) during surgery\n* Expected surgical duration of at least 2 hours\n\nExclusion Criteria:\n\n* Emergency surgery\n* Continuous infusion of remifentanil or propofol for less than 30 minutes during surgery\n* Receiving continuous intravenous sedatives other than propofol during the maintenance phase\n* Receiving continuous intravenous analgesics other than remifentanil during the maintenance phase\n* Inhaled anesthetic maintenance concentration not equal to 0.5 MAC\n* Known allergy to propofol or remifentanil\n* Severe obesity (BMI \\>= 35 kg\u002Fm2)\n* Severe cardiovascular disease (NYHA class IV heart failure, unstable angina, or recent myocardial infarction within 30 days)\n* Participation in another interventional clinical trial within 30 days",{"count":188,"type":21},40,[90],"This proof-of-concept randomized controlled trial evaluates a reinforcement learning (RL)-based clinical decision support system for intraoperative hemodynamic management during non-cardiac surgery.\n\nBackground: Intraoperative hypotension is common during general anesthesia and is associated with adverse outcomes including acute kidney injury, myocardial injury, and increased mortality. Current hemodynamic management relies on the individual anesthesiologist's clinical judgment, which can vary in consistency and timeliness. An RL-based system that learns optimal vasoactive agent dosing strategies from clinical data may help standardize and improve real-time hemodynamic decision-making.\n\nPurpose: The primary objective is to evaluate whether the RL-based decision support system can learn intraoperative hemodynamic management decisions comparable to those of experienced anesthesiologists, as measured by the mean absolute error (MAE) between RL-recommended and clinician-executed vasoactive agent doses. The secondary objective is to assess whether RL-guided management improves clinical hemodynamic outcomes, including the time-weighted average of hypotension and the percentage of time with mean arterial pressure within the target range.\n\nParticipants: Adult patients (aged 18 to 85 years, ASA I-IV) scheduled for elective non-cardiac surgery under general anesthesia with continuous invasive arterial blood pressure monitoring.\n\nProcedures: Participants will be randomly assigned (1:1) to one of two groups. In the RL-guided group, the anesthesiologist will receive real-time vasoactive agent dosing recommendations from the decision support system displayed on a bedside screen; the anesthesiologist retains full clinical autonomy over all final decisions. In the standard care group, the anesthesiologist will manage hemodynamics according to institutional standard practice without input from the system. The patient and the outcomes assessor will be masked to group assignment. Data collection covers the intraoperative period and 30-day postoperative follow-up.",[192,193],"Intraoperative Hypotension","Hemodynamic Instability",[195,196,197,168,198],"Reinforcement Learning","Clinical Decision Support System","Depth of Anesthesia","Vasoactive Agent Dosing","2026-04-01",{"date":201,"type":36},"2026-04-06",{"date":203,"type":21},"2026-06-01",{"date":205,"type":21},"2027-12-15",{"name":42,"class":43},2,{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":88,"phases":219,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":44},"100632250","scs-therapy-for-patients-with-bladder-and-bowel-dysfunction-after-sci-100632250","NCT07511244","SCS Therapy for Patients With Bladder and Bowel Dysfunction After SCI","Clinical Trial on the Safety and Efficacy of Spinal Cord Stimulation Therapy for Patients With Bladder and Bowel Dysfunction After Spinal Cord Injury","SCSBBD","Inclusion Criteria:\n\n* Age: 18 to 60 years old\n* Spinal Cord Injury Classification: AIS Grade A, B, C, or D\n* Injury Duration: \\> 6 months\n* Stable and healthy condition, as determined by the investigator; able to complete the entire study period and cooperate with examinations\n* Voluntary participation in clinical trial and ability to sign informed consent form\n* Good patient compliance, willing and able to follow follow-up requirements during the follow-up period\n\nExclusion Criteria:\n\n* Mental Disorders Patients with obvious mental illnesses (such as anxiety, depression, etc.) who are unable to complete relevant subjective scoring.\n* Mental and Cognitive Impairments Patients with mental or cognitive disorders who are unable to cooperate with surgeries, undergo programming procedures, or complete follow - up.\n* Autonomic Reflex Disorders Patients with severe autonomic reflex disorders.\n* Inability in Surgical and Follow - up Processes Patients who are unable to undergo spinal cord stimulation surgery or cooperate with follow - up.\n* Spinal Abnormalities Patients accompanied by progressive spinal instability or severe spinal deformities.\n* Life Expectancy Patients with an expected lifespan of less than one year.\n* Laboratory Abnormalities and Surgical Tolerance Patients with abnormal blood routine, blood biochemistry, etc., and are clinically judged to be unable to tolerate surgery, such as those with coagulation disorders, abnormal liver and kidney function.\n* Cardiovascular and Respiratory Diseases Patients with uncontrolled hypertension, severe heart diseases, or severe internal medicine and respiratory system diseases, or those who have regularly taken medications related to hypertension and heart diseases within the recent three months.\n* Renal Disorders Patients with severe hydronephrosis or renal function disorders.\n* Urogenital Function Disorders before Spinal Cord Injury Patients with pre - existing urethral sphincter or bladder dysfunction before spinal cord injury.\n* History of Pelvic Surgery and Radiotherapy Patients with a history of pelvic radiotherapy, bladder cancer, or other bladder surgeries that affect the basic bladder physiology.\n* Other Inappropriate Cases Patients considered inappropriate by the researchers.","60 Years",{"count":218,"type":21},10,[90],"This clinical trial aims to evaluate the safety and efficacy of spinal cord stimulation (SCS) in treating patients with urinary and bowel dysfunction after spinal cord injury (SCI). SCI is a highly disabling condition that can lead to sensory, motor, and autonomic nervous system dysfunction below the injury level. Neurogenic bladder and bowel dysfunction are common sequelae of SCI, seriously affecting patients' quality of life. Currently, clinical treatments can only partially alleviate urinary and bowel dysfunction, and more effective therapeutic approaches are still needed. Existing clinical studies have shown that SCS is gradually being applied to treat neurogenic bladder and bowel dysfunction in SCI patients. SCS can significantly improve urinary efficiency, bladder capacity, compliance, and detrusor pressure in SCI patients, thereby enhancing their quality of life. The main questions this study aims to answer include: 1. Can this protocol help patients restore partial urinary and bowel function? 2. Besides the restoration of partial urinary and bowel function , can the SCS therapy could also help patients to restore the walking function.\n\nPatients with urinary and bowel dysfunction more than 6 months after spinal cord injury will undergo epidural spinal stimulation electrode implantation surgery two weeks after functional assessment. Then the parameter optimization and rehabilitation will last for 6 months. The follow-up records and assessments will be conducted monthly at 2, 4, and 6 months after surgery.",[222,223],"Bladder and Bowel Dysfunction","SCI - Spinal Cord Injury",[222,225],"Spinal Cord Injury","2026-03-30",{"date":201,"type":36},{"date":229,"type":36},"2024-12-01",{"date":231,"type":21},"2029-12-31",{"name":42,"class":43},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":88,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":44},"100618216","one-vs-three-hipec-cycles-after-crs-for-pseudomyxoma-peritonei-100618216","NCT07328737","One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei","Efficacy and Safety of One vs Three Cycles of Hyperthermic Intraperitoneal Chemotherapy After Cytoreductive Surgery for Pseudomyxoma Peritonei: A Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Voluntarily consent to participate, sign informed consent, and be willing and able to comply with the study protocol;\n2. Age 18-70 years;\n3. Undergo CRS+HIPEC with pathological diagnosis of PMP of high grade with signet-ring cells, high grade, or low grade;\n4. Karnofsky performance status (KPS) \\>60;\n5. Adequate function of major organs as follows:\n\n   1. Hematology: WBC ≥3.5×10\\^9\u002FL, ANC ≥1.0×10\\^9\u002FL, LC ≥0.5×10\\^9\u002FL, PLT ≥80×10\\^9\u002FL, Hb ≥90 g\u002FL;\n   2. Hepatic function: AST, ALT, and TBIL ≤2×upper limit of normal (ULN);\n   3. Renal function: serum creatinine \\\u003C1.2×ULN;\n   4. Coagulation: APTT ≤1.5×ULN; INR or PT ≤1.5×ULN;\n   5. Cardiopulmonary function sufficient to tolerate major surgery and HIPEC;\n\n(5) Radiological Peritoneal Cancer Index (PCI) ≥15; (6) No local or systemic antitumor therapy within 1 month prior to CRS+HIPEC; (7) Adverse reactions from prior treatments have resolved before study initiation or, in the investigator's judgment, will not interfere with this study;\n\nExclusion Criteria:\n\n1. Metastases to lung, brain, bone, or liver;\n2. AST, ALT, or TBIL ≥2×ULN;\n3. Serum creatinine ≥1.2×ULN;\n4. Severe mesenteric contraction;\n5. Major organ dysfunction that cannot support the planned procedures;\n6. Concomitant hematological disorders or other malignancies;\n7. Acute or subacute infectious disease;\n8. History of allergy to cisplatin or docetaxel, or marked allergic diathesis or severe allergy history;\n9. Psychiatric or psychological disorders preventing cooperation with treatment and efficacy evaluation;\n10. Any other condition deemed unsuitable for enrollment by the investigator;","70 Years",{"count":242,"type":21},132,[90],"The goal of this clinical trial is to compare the efficacy and safety of one versus three sessions of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for patients with pseudomyxoma peritonei (PMP).\n\nThe main questions it aims to answer are:\n\n* Does receiving three HIPEC sessions lead to better Progression-Free Survival (PFS) and Overall Survival (OS) compared to one session?\n* What are the differences in postoperative complications (e.g., infection, bowel obstruction, myelosuppression) and organ toxicity (e.g., liver\u002Fkidney injury) between the two regimens?\n* How do the different treatment schedules impact patients' quality of life?\n\nResearchers will compare the experimental group (3 HIPEC sessions) to the control group (1 HIPEC session) to investigate the efficacy and safety of the additional sessions.\n\nParticipants will:\n\n* Be randomly assigned to one of two groups:\n\n  1. Control Group: Receive only a single intraoperative HIPEC session following CRS.\n  2. Experimental Group: Receive two additional HIPEC sessions after CRS+HIPEC (on post-operative day 2 and day 4) at reduced drug doses.\n* Undergo scheduled safety checks for side effects on days 1, 3, 5, 7, and 10 post-HIPEC.\n* Attend a follow-up visit at 1 month after CRS+HIPEC and, if eligible, receive 6 cycles of standard postoperative chemotherapy.\n* Attend regular long-term follow-up visits for several years, which will include physical examinations, blood tests (for tumor markers), CT scans, and quality-of-life questionnaires (EORTC QLQ-C30 version 3.0).",[246],"Pseudomyxoma Peritonei","2025-12-28",{"date":249,"type":36},"2026-01-09",{"date":251,"type":36},"2025-11-01",{"date":253,"type":21},"2030-11-01",{"name":42,"class":43},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":262,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":44},"100604667","host-microbe-interactions-in-biliary-dilatation-100604667","NCT07152496","Host-Microbe Interactions in Biliary Dilatation","Integrated Transcriptome-Microbiome Profiling Reveals Host-Microbe Crosstalk in Biliary Dilatation","Inclusion Criteria:\n\nPatients who have been definitively diagnosed with biliary dilatation and are scheduled for surgical resection (Disease group) Healthy donor bile duct tissues discarded during organ transplantation procedures as part of routine surgical preparation (Control group)\n\nExclusion Criteria:\n\nPatients with severe systemic diseases that may affect study outcomes (Disease group) Insufficient tissue sample quality or quantity (Disease group) Unavailable or inadequate donor bile duct tissue samples (Control group)",true,{"count":264,"type":21},400,"This study is an observational cohort study aimed at continuously enrolling patients with biliary dilatation and healthy controls. It will collect bile duct tissue samples and clinical data from participants across all age groups to establish a comprehensive cohort for biliary dilatation research. Based on this cohort, the study seeks to investigate the molecular mechanisms underlying biliary dilatation development and progression, explore the role of host-microbiome interactions in disease processes, and identify biomarkers associated with complications and malignancy risk, to establish evidence-based strategies for improved diagnosis and treatment of biliary dilatation.",[25],[268,269,270],"molecular mechanism","Biliary Dilatation","microbiome","2025-12-07",{"date":273,"type":36},"2025-12-09",{"date":275,"type":21},"2025-12-15",{"date":277,"type":21},"2026-07-01",{"name":42,"class":43},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":216,"enrollmentInfo":286,"targetDuration":4,"studyType":88,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":4},"100599715","the-clinical-study-of-bone-patellar-tendon-bone-and-quasi-anatomical-meniscus-allograft-transplantation-technique-100599715","NCT07088094","The Clinical Study of Bone-patellar Tendon-bone and Quasi-anatomical Meniscus Allograft Transplantation Technique","BPTB，Meniscus","Inclusion Criteria:\n\n* Aged 18-50 years\n* Clinical diagnosis of symptomatic meniscal deficiency and anterior cruciate ligament injury (complete rupture or severe damage)\n* Failure of conservative treatment (e.g., physical therapy, analgesia) for ≥6 months\n* Stable knee joint (no ligamentous instability confirmed via clinical exam and MRI)\n* Willingness to comply with postoperative rehabilitation and follow-up evaluations\n\nExclusion Criteria:\n\n* Severe tibiofemoral osteoarthritis (Kellgren-Lawrence grade ≥3)\n* History of prior knee infection or septic arthritis\n* Inflammatory arthritis (e.g., rheumatoid arthritis, gout)\n* BMI ≥35 kg\u002Fm²\n* Pregnancy or planning pregnancy during the study period\n* Concurrent full-thickness chondral defects (Outerbridge grade III-IV) in the affected compartment\n* Inability to undergo MRI (e.g., claustrophobia, metallic implants)",{"count":287,"type":21},200,[90],"This clinical study investigates the outcomes of bone-patellar tendon-bone and quasi-anatomical meniscus allograft transplantation techniques in patients requiring joint reconstruction. The study aims to assess the safety, efficacy, and functional improvements following these transplant procedures, utilizing donor tissues to restore joint function and alleviate pain in individuals with severe knee damage. Participants will undergo the transplantation procedure and be monitored for post-operative recovery, complications, and long-term outcomes, including joint stability and mobility. The study seeks to provide valuable insights into the effectiveness of these advanced surgical techniques for knee joint repair.",[291,292],"Meniscal Tears","ACL - Anterior Cruciate Ligament Rupture","2025-07-17",{"date":295,"type":36},"2025-07-28",{"date":297,"type":21},"2025-08-01",{"date":299,"type":21},"2028-05-31",{"name":42,"class":43},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":317,"leadSponsor":319,"locationsCount":44},"100595776","efficacy-and-safety-of-surgical-treatment-for-type-iva-cbd-100595776","NCT07036848","Efficacy and Safety of Surgical Treatment for Type IVa CBD","The Efficacy and Safety of Surgical Treatment in Type IVa Congenital Biliary Dilation: A Multi-center Cohort Study","Inclusion Criteria:\n\n1. Patients who have been diagnosed with Todani type IVa BD.\n2. Patients aged between 0 and 80 years old, regardless of gender.\n3. First-time receipt of surgery.\n\nExclusion Criteria:\n\n1. With abnormal intrapancreatic bile duct\n2. Inappropriate Roux-loop length (outside the range of 40-60 cm for adults and 15-30 cm for children)\n3. With non-relevant surgical interventions\n4. Pathologically confirmed carcinogenesis\n5. Unresolved choledocholithiasis, bile duct stenosis, and Intrahepatic bile duct stones during the procedure.\n6. Unavailable follow-up information.",{"count":309,"type":21},1500,"This study is a multicenter, bidirectional cohort study aimed at continuously enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for IVa biliary dilatation (BD). Based on this cohort, the study seeks to compare the perioperative risks, long-term outcomes, and quality of life of type IVa BD following surgical treatment, to establish standardized surgical treatment strategies for type IVa BD.",[25],[313],"Biliary Dilatation, Cohort Study, Surgical Treatment","2025-07-14",{"date":293,"type":36},{"date":314,"type":36},{"date":318,"type":21},"2035-07-01",{"name":42,"class":43},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":329,"conditions":330,"keywords":338,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":44},"100598351","digital-early-warning-system-for-acute-lung-injury-in-liver-surgery-100598351","NCT07070362","Digital Early Warning System for Acute Lung Injury in Liver Surgery","The Construction of a Digital Intelligence Early Warning System for the Whole Process of Acute Lung Injury in Liver Surgery Based on Cardiopulmonary Interaction Characteristics","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing major liver surgery (including two-segment or more hepatectomy, liver transplantation, etc.)\n* Voluntary participation with signed informed consent",{"count":328,"type":21},4000,"This study focuses on developing an explainable machine learning model based on cardiopulmonary interaction characteristics to achieve early prediction of acute lung injury (ALI) in patients undergoing major liver surgery. The research will establish a digital early-warning system for ALI to provide support for clinical diagnosis and treatment decisions, thereby reducing the incidence and fatality rate of ALI.",[331,332,333,334,335,336,337],"Acute Lung Injury(ALI)","Liver Cirrhosis","ARDS, Human","MASLD","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","NAFLD (Nonalcoholic Fatty Liver Disease)","Liver Cancer, Adult",[339,340,341,342,343],"Digital Intelligence","Acute Lung Injury","PPCs","Liver Surgery","Cardiopulmonary Interaction;","2025-07-08",{"date":293,"type":36},{"date":347,"type":36},"2024-11-01",{"date":349,"type":21},"2027-11-30",{"name":42,"class":43},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":4},"100597450","downstaging-prediction-model-for-hcc-100597450","NCT07058649","Downstaging Prediction Model for HCC","Individualized Downstaging Prediction Model for HCC Beyond the UCSF Criteria","Inclusion Criteria:\n\n* (A) Adult patients with HCC over the age of 18 (clinically diagnosed or pathologically diagnosed); (B) Liver function Child-Pugh score of Class A, or Class B with a score of 7 or below (including 7); (C) A single solid tumor with a diameter of ≥6.5 cm; three or more lesions, among which at least one tumor has a diameter \\>4.5 cm or the sum of the diameters is ≥8 cm; invasion of major blood vessels regardless of tumor size and number.\n\nExclusion Criteria:\n\n* (A) Presence of distant metastasis outside the liver; (B) General performance status score (PS score) greater than 2 points.",{"count":359,"type":21},369,"This study is a real-world, single-center study that collects imaging and clinical data from patients with HCC who are downstaged beyond the UCSF criteria.",[362],"HCC - Hepatocellular Carcinoma",[364,365],"downstaging","UCSF","2025-07-01",{"date":368,"type":36},"2025-07-10",{"date":370,"type":21},"2025-07-16",{"date":372,"type":21},"2027-12-01",{"name":42,"class":43},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":382,"minAge":52,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":4},"100596399","oteseconazole-in-the-treatment-of-adults-with-vulvovaginal-candidiasisvvc-100596399","NCT07044947","Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）","Non-interventional Real-World Study of Oteseconazole in the Treatment of Vulvovaginal Candidiasis","VVC","Inclusion Criteria:\n\n* ≥ 18 years old, female; vulvovaginal signs and symptoms (VSS) score ≥7; Plan to use oteseconazole monotherapy or combination therapy\n\nExclusion Criteria:\n\n* Evidence has shown that the patient whohas been pregnant or lactating; Patients who are participating in or planning to participate in other interventional clinical studies; Other situations determined by the researcher as unsuitable for inclusion in the study","FEMALE",{"count":384,"type":21},3000,"Oteseconazole is a novel, oral, highly selective inhibitor of fungal CYP51. Oteseconazole showed statistically significant and clinically meaningful treatment of severe VVC and was generally tolerated. The trial is a national multi-center, non-interventional observational real-world study, aiming to evaluate the effecacy and safety of oteseconazole in the treatment of patients with VVC. This study will include patients with severe vulvovaginal candidiasis (SVVC) . It is divided into prospective and retrospective parts.",[387],"Vulvovaginal Candidiasis","2025-06-23",{"date":366,"type":36},{"date":391,"type":21},"2025-08-10",{"date":393,"type":21},"2030-08-10",{"name":42,"class":43},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":401,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":44},"100593458","a-population-based-cohort-of-osteoarthritis-the-tsinghua-university-tiantongyuan-community-osteoarthritis-study-100593458","NCT07006701","A Population-based Cohort of Osteoarthritis: the Tsinghua University Tiantongyuan Community Osteoarthritis Study","Inclusion Criteria:\n\n* Aged 50 years and above\n* Long-term resident of the study area\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Hearing, speech, or mental impairments preventing effective communication\n* Unable to complete scheduled follow-up visits\n* Pregnant or planning pregnancy during the study period\n* Any other condition deemed unsuitable for participation by the researchers","50 Years",{"count":328,"type":21},"The purpose of this study is to examine the natural history and risk factors of osteoarthritis (OA) and to explore the relationship between metabolic factors and OA progression.",[405],"Osteoarthritis","2025-05-27",{"date":408,"type":36},"2025-06-05",{"date":410,"type":21},"2025-06-03",{"date":412,"type":21},"2034-12-31",{"name":42,"class":43},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":401,"maxAge":18,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":44},"100592220","a-multi-center-bidirectional-cohort-study-on-total-knee-arthroplasty-for-the-treatment-of-knee-osteoarthritis-100592220","NCT06990594","A Multi-Center Bidirectional Cohort Study on Total Knee Arthroplasty for the Treatment of Knee Osteoarthritis","Inclusion Criteria:\n\n1. Patients aged 50-80 years.\n2. Diagnosed with end-stage knee osteoarthritis, post-traumatic arthritis, avascular necrosis, or inflammatory arthritis requiring total knee arthroplasty.\n3. Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n1. History of prior knee surgery or knee replacement.\n2. Severe knee deformity (valgus \\>20° or varus \\>15°) or instability.\n3. Severe contracture (\\>25° flexion contracture).\n4. Undergoing total knee revision surgery.\n5. Rheumatoid arthritis diagnosis.\n6. BMI \\>35.\n7. Neuromuscular disorders affecting knee stability or gait.\n8. Pregnancy or lactation.\n9. Presence of significant comorbidities posing unacceptable risk.\n10. Active or recent severe infections or malignancy.\n11. History of drug or alcohol abuse in the past six months.",{"count":421,"type":21},120,"The purpose of this study is to evaluate the clinical benefits of different types of total knee arthroplasty (TKA) in osteoarthritis treatment. The study aims to compare surgical outcomes, functional recovery, complication rates, and cost-effectiveness among personalized, semi-personalized, and conventional TKA in a multi-center, bidirectional cohort study.",[405],"2025-05-17",{"date":426,"type":36},"2025-05-25",{"date":428,"type":21},"2025-06-01",{"date":430,"type":21},"2027-12-31",{"name":42,"class":43},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":440,"targetDuration":442,"studyType":22,"phases":4,"briefSummary":443,"conditions":444,"keywords":445,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":44},"100588211","relationship-between-fgf19-overexpression-and-disease-prognosis-100588211","NCT06938451","Relationship Between FGF19 Overexpression and Disease Prognosis","A Real-world Study of FGF19 Overexpression Status and Treatment Outcome and Prognosis in Advanced Hepatocellular Carcinoma","FGF19","Inclusion Criteria:\n\n* Age ≥18 years on the day of signing the informed consent form\n* Histologically or clinically confirmed diagnosis of intermediate to advanced HCC\n* Adequate tissue samples of previous liver cancer\n* Expected survival of more than 3 months\n\nExclusion Criteria:\n\n* Fibrous laminae or sarcomatoid HCC or mixed HCC-ICC, or other rare non-HCC pathologic subtypes\n* Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate",{"count":441,"type":21},100,"3 Years","A real-world study of FGF19 overexpression status and treatment outcome and prognosis in advanced hepatocellular carcinoma",[165],[438,446,447],"hepatocellular carcinoma","HCC","2025-04-14",{"date":450,"type":36},"2025-04-22",{"date":452,"type":21},"2025-05-01",{"date":454,"type":21},"2028-12-31",{"name":42,"class":43},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":18,"enrollmentInfo":462,"targetDuration":4,"studyType":88,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":476,"locationsCount":4},"100586408","a-prospective-multicenter-randomized-controlled-trial-of-flexible-and-navigable-suction-ureteral-access-sheath-combined-with-needle-perc-for-the-treatment-of-partial-staghorn-renal-calculi-100586408","NCT06914986","A Prospective Multicenter Randomized Controlled Trial of Flexible And Navigable Suction Ureteral Access Sheath Combined With Needle Perc for the Treatment of Partial Staghorn Renal Calculi","Inclusion Criteria:\n\n1. Aged 18-80 years\n2. CT scan indicates partial staghorn calculi\n3. Able to complete the study in accordance with the protocol requirements\n4. Informed about the study and has signed the informed consent form\n\nExclusion Criteria:\n\n1. Severe renal insufficiency (GFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²)\n2. Significant calyceal hydronephrosis (calyceal width ≥ 2 cm)\n3. Renal stone volume \\> 33.5 cm³\n4. Renal stones or nephrocalcinosis caused by genetic diseases or definite metabolic disorders that have not been ruled out, such as renal tubular acidosis, primary hyperoxaluria, primary hyperparathyroidism, etc.\n5. Congenital or structural renal abnormalities: spinal deformity, ankylosing spondylitis, horseshoe kidney, medullary sponge kidney, duplicated kidney, polycystic kidney, ectopic kidney, etc.\n6. History of previous open renal stone surgery\n7. Patients with uncontrolled urinary tract infections\n8. Subjects deemed by the investigator to have other factors that make them unsuitable for participation in this trial",{"count":463,"type":21},344,[90],"The goal of this clinical trial is to learn if flexible and navigable suction ureteral access sheath combined with needle perc works to treat partial staghorn renal calculi. It will also learn about the safety of drug ABC. The main questions it aims to answer are:\n\n* Does flexible and navigable suction ureteral access sheath combined with needle perc result in similar stone free rate compared with PCNL\n* Does flexible and navigable suction ureteral access sheath combined with needle perc result in more complications compared with PCNL Researchers will compare flexible and navigable suction ureteral access sheath combined with needle perc result in similar stone free rate compared with PCNL to see if flexible and navigable suction ureteral access sheath combined with needle perc works to treat partial staghorn renal calculi.\n\nParticipants will:\n\n* Performed flexible and navigable suction ureteral access sheath combined with needle perc or PCNL\n* Visit the clinic after surgery 1 month and 3 month for checkups and tests",[467],"Urinary Calculi",[469],"partial staghorn renal calculi","2025-04-01",{"date":472,"type":36},"2025-04-07",{"date":470,"type":21},{"date":475,"type":21},"2028-03-01",{"name":42,"class":43},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":88,"phases":487,"briefSummary":489,"conditions":490,"keywords":492,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":505},"100573784","phase-4-the-effects-of-xuezhikang-and-atorvastatin-on-lipid-in-patients-with-dyslipidemia-and-prediabetes-100573784","NCT06750783","The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes","A Randomized Controlled Study on the Effects of Xuezhikang and Atorvastatin on Blood Glucose and Lipid Levels in Patients With Dyslipidemia and Prediabetes","Xuezhikang","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* No gender restrictions;\n* Definition of pre diabetes: All subjects were tested with 75g OGTT to measure fasting and 2h venous serum glucose and glycosylated hemoglobin. Fasting blood glucose ≥ 6.1 and \\\u003C 7mmol\u002FL, 2-hour serum glucose ≥ 7.8 and \\\u003C 11.1mmol\u002FL after glucose load, and glycated hemoglobin\\\u003C6.5%;\n* Abnormal lipid metabolism: LDL-c ≥ 3.4 mmol\u002FL and\\\u003C4.9 mmol\u002FL, and TG ≤ 5.6 mmol\u002FL; (2) Non-HDL-c ≥ 4.1mmol\u002FL and\\\u003C5.7 mmol\u002FL, and TG ≤ 5.6 mmol\u002FL;\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients who have met the diagnosis of diabetes;\n* Within 3 months prior to signing the informed consent form, there was an acute coronary syndrome, stroke, or transient ischemic attack.\n* ALT\u002FAST\\>3 times ULN;\n* Known myopathy, rhabdomyolysis, or creatine kinase levels greater than 4-fold ULN, and not caused by muscle injury;\n* Pregnant or planning to conceive;\n* Have used any lipid-lowering drugs within 3 months;\n* Individuals with allergies\u002Fcontraindications to Xuezhikang and Atorvastatin.\n* Suffering from any of the following diseases: uncontrolled hyperthyroidism and hypothyroidism, severe heart failure, malignant tumors, hematopoietic system diseases, digestive system diseases affecting digestion and\u002For absorption function, mental disorders, other serious or unstable physical diseases.\n* History of alcohol or drug abuse or dependence within 3 months prior to joining the trial.\n* Participated in clinical trials of other drugs or devices within 3 months prior to joining the trial.\n* Researchers believe that other situations are not suitable for participating in the experiment.",{"count":486,"type":21},398,[488],"PHASE4","This study compares the impact of Xuezhikang and atorvastatin on glucose metabolism to explore the incidence of prediabetes patients developing diabetes after 24 weeks of Xuezhikang use, and by investigating the effect of Xuezhikang on blood glucose fluctuations, discusses the possible mechanisms by which Xuezhikang affects glucose metabolism.",[491],"Prediabetic State (IGT)",[493,494,495,496,497],"XUEZHIKANG","atorvastatin","glucose metabolism","blood glucose fluctuations","diabetes",{"date":499,"type":36},"2025-04-03",{"date":501,"type":36},"2024-12-31",{"date":503,"type":21},"2026-03-31",{"name":42,"class":43},3,{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":262,"sex":17,"minAge":513,"maxAge":4,"enrollmentInfo":514,"targetDuration":516,"studyType":22,"phases":4,"briefSummary":517,"conditions":518,"keywords":521,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":531,"leadSponsor":532,"locationsCount":207},"100585814","wearable-ecg-for-af-screening-and-stroke-risk-assessment-100585814","NCT06907264","Wearable ECG for AF Screening and Stroke Risk Assessment","Application of Wearable ECG Garments in Atrial Fibrillation Screening and Stroke Risk Assessment","Inclusion Criteria:\n\n1. Age ≥ 40 years.\n2. High-risk stroke population identified by the \"8+2\" risk score in stroke screening.\n3. Ability to operate the device independently or with assistance from family members.\n4. Willingness to participate in the study and provide signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with severe diseases that limit device wear (e.g., advanced malignant tumors, severe infections, Class IV heart failure) or those receiving hospice care.\n2. Patients unable to operate the device or understand the study procedures due to cognitive impairment, mental illness, or language communication barriers.\n3. Patients who may experience severe discomfort or allergic reactions from wearing the device.\n4. Patients already using implanted cardiac monitoring devices.","40 Years",{"count":515,"type":21},243,"12 Months","This study aims to evaluate the application of wearable ECG garments in atrial fibrillation (AF) screening and stroke risk assessment. Using a prospective, multicenter, observational design, the study will recruit high-risk stroke patients aged 40 and above to undergo 24-hour continuous ECG monitoring with wearable ECG garments. The study will assess the detection rate of AF and explore the correlation between heart rate variability (HRV) parameters and stroke risk. Additionally, the study will analyze the association between P-wave indices and AF, and evaluate the acceptability of the device among patients and healthcare providers. The primary goal is to validate the accuracy of wearable ECG garments in AF detection and explore their predictive value for stroke risk in high-risk populations.",[519,520],"Atrial Fibrillation","Stroke",[522,523,520,524,525,526],"Wearable ECG garment","Atrial fibrillation","Heart rate variability","Observational study","High-risk stroke population","2025-03-26",{"date":529,"type":36},"2025-04-02",{"date":470,"type":21},{"date":430,"type":21},{"name":42,"class":43},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":88,"phases":542,"briefSummary":543,"conditions":544,"keywords":546,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":44},"100541596","assessing-the-effectiveness-of-continuous-glucose-monitoring-in-enhancing-surgical-outcomes-for-patients-with-diabetes-100541596","NCT06331923","Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes","Assessing the Effectiveness of Continuous Glucose Monitoring Compared with Conventional Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes: a Multi-center, Parallel-arm, Randomized, Pragmatic Trial in China","Inclusion Criteria:\n\n1. Patients aged above 18 years;\n2. Patients with diabetes mellitus or impaired glucose tolerance;\n3. Expected major thoracic and abdominal surgery (except cardiac surgery; including endoscopic surgery and robotic surgery), open orthopedic surgery, neurosurgery;\n4. Volunteered for this study and written informed consent.\n\nExclusion Criteria:\n\n1. The patient refused;\n2. The time between wearing CGM sensor and surgical skin incision cannot meet 6 hours or more;\n3. Expected monitoring time less than 72 hours in CGM group;\n4. Patients had comorbidities that affected the evaluation of endpoints;\n5. The attending physician thought that the patient had inappropriate indications for enrollment;\n6. Participants were involved in other studies that interfered with the evaluation of the results of this study.",{"count":541,"type":21},10168,[90],"The goal of this multi-center, pragmatic, randomized controlled trial is to assess the effectiveness of continuous glucose monitoring (CGM) compared with conventional monitoring in enhancing surgical outcomes for diabetic patients. The main questions it aims to answer are:\n\n* To assess the effectiveness of CGM compared with conventional monitoring in reducing the comprehensive complication index (CCI) for patients with diabetes or impaired glucose tolerance (IGT) within 30 days after surgery.\n* To analyze the impact of different age groups, types of surgery, preoperative levels of HbA1c, and preoperative 24h glycemic variations on the improvement of surgical outcomes under the CGM model.\n\nParticipants will receive CGM prescribed by the attending physician for at least 6 hours before surgery. Glucose monitoring should be continued until the 7th day after surgery or discharge.\n\nThe investigators will compare conventional monitoring group to see if CGM could reduce the CCIs for patients with diabetes or impaired glucose tolerance within 30 days after surgery.",[545],"Comprehensive Complication Index",[547,548,549,550],"comprehensive complication index","continuous glucose monitoring","perioperative","prognosis",{"date":552,"type":36},"2025-03-27",{"date":554,"type":36},"2024-04-12",{"date":556,"type":21},"2025-12-31",{"name":42,"class":43},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":401,"enrollmentInfo":564,"targetDuration":4,"studyType":88,"phases":566,"briefSummary":567,"conditions":568,"keywords":570,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":579,"leadSponsor":580,"locationsCount":4},"100584598","prognosis-analysis-of-three-surgical-techniques-for-arthroscopic-anterior-cruciate-ligament-reconstruction-100584598","NCT06891430","Prognosis Analysis of Three Surgical Techniques for Arthroscopic Anterior Cruciate Ligament Reconstruction","Inclusion Criteria:\n\nDiagnosed with anterior cruciate ligament (ACL) rupture; Age between 18-50 years; All patients must have isolated anterior cruciate ligament (ACL) rupture; Knee joint degeneration \\\u003C KL grade II, and intraoperative cartilage injury \\\u003C ICRS grade III; All isolated ACL rupture patients must not have other ligament injuries; If accompanied by meniscus injury, the proportion of medial or lateral meniscus resection during surgery must not exceed 40%; The duration of the condition must be within one year after injury; No restriction on body weight; The cause of ACL rupture must be sports-related trauma or twisting injuries, excluding car accident injuries.\n\nExclusion Criteria:\n\nPatients with other surgical contraindications; Patients with poor compliance; Patients planning pregnancy; Patients deemed unsuitable for inclusion by the researchers.",{"count":565,"type":21},180,[90],"This study hypothesizes that the tunnel positioning and drilling direction in two single-bundle reconstruction techniques (Anatomical Single-Bundle Reconstruction, ASBR, and Central Axial Single-Bundle Reconstruction, CASBR) influence the biomechanical environment of the graft, thereby affecting graft remodeling and maturation, ultimately impacting postoperative outcomes. Studies have shown that the graft bending angle (GBA) is a critical factor affecting graft ligamentization. ASBR, with a higher GBA, may result in poorer graft maturation, while CASBR, with a lower GBA, may provide a more favorable biomechanical environment. Additionally, graft volume has been identified as an important factor influencing postoperative graft maturation. Therefore, this study also examines the double-bundle reconstruction (DBR) technique, which has a GBA similar to CASBR.\n\nThe Impact of Three Techniques on Graft Maturation Anatomical Single-Bundle Reconstruction (ASBR)\n\nASBR involves drilling a single tunnel at both the femoral and tibial ends, with the tunnel positioned at the center of the dense fiber area of the ACL footprint. The femoral tunnel is positioned at 90° knee flexion and drilled at 120°, while the tibial tunnel is positioned at 70° knee flexion. Due to the higher GBA in ASBR, the graft may experience greater bending stress during motion, leading to impaired graft maturation, limited ligamentization, and increased stress concentration around the tunnel, potentially causing tunnel widening.\n\nCentral Axial Single-Bundle Reconstruction (CASBR)\n\nCASBR also involves drilling a single tunnel at both ends, but the tunnel is positioned in the posterior region of the dense fiber area of the ACL footprint, mimicking the central axis of the native ACL. The femoral tunnel is positioned at 90° knee flexion and drilled at 120°, while the tibial tunnel is positioned at 70° knee flexion. Compared to ASBR, CASBR's lower GBA results in more uniform graft stress distribution, promoting better graft maturation and reducing the risk of stress concentration and tunnel widening.\n\nDouble-Bundle Reconstruction (DBR)\n\nDBR involves drilling two tunnels at both the femoral and tibial ends, targeting the dense fiber areas of the anterior medial bundle (AMB) and posterior lateral bundle (PLB) of the ACL footprint. The positioning of the PLB tunnel is similar to CASBR, while the AMB tunnel is located in the anterior region of the footprint. DBR provides a more anatomically accurate distribution of forces, leading to a more even biomechanical environment. However, the increased number of tunnels may complicate stress distribution.\n\nImpact on Postoperative Outcomes ASBR, with its higher GBA, may lead to poor graft maturation and increased tunnel widening. CASBR, with a lower GBA, offers a more favorable biomechanical environment for graft maturation. While DBR ensures a more uniform force distribution, the additional tunnels may introduce complexities in stress distribution, potentially affecting postoperative recovery and return to sports (RTS).",[569],"Anterior Cruciate Ligament Tear",[571,572,573,574],"tunnel widening","Anterior Cruciate Ligament","double-bundle reconstruction","single-bundle reconstruction","2025-03-17",{"date":577,"type":36},"2025-03-24",{"date":470,"type":21},{"date":428,"type":21},{"name":42,"class":43},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":18,"enrollmentInfo":587,"targetDuration":4,"studyType":88,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":44},"100582101","assessing-the-efficacy-of-a-preoperative-navigation-system-in-anterior-cruciate-ligament-reconstruction-100582101","NCT06858930","Assessing the Efficacy of a Preoperative Navigation System in Anterior Cruciate Ligament Reconstruction","Inclusion Criteria:\n\n1. Preoperatively, the participant or guardian is willing and able to sign the informed consent form;\n2. Patients aged 18 to 80 years (inclusive of 18 and 80 years), regardless of gender;\n3. Patients who meet the diagnostic criteria for anterior cruciate ligament (ACL) tear and have no contraindications for implantation;\n4. Patients with mature skeletons;\n5. Good compliance and willingness and ability to participate in follow-up observations as required.\n\nExclusion Criteria:\n\n* (1) Participants who have previously participated in other clinical studies of drugs, biological agents, or medical devices but did not meet the primary study endpoint within the specified timeframe; (2) Patients with a known allergy to one or more implanted materials; (3) Patients who are physically frail or unable to tolerate surgery due to other systemic diseases; (4) Presence of active infectious lesions in the knee joint or other parts of the body; (5) Obesity with a BMI \\> 35; (6) Patients with severe diabetes (acute complications of diabetes, preoperative random blood glucose ≥ 16.7 mmol\u002FL with or without altered consciousness, such as diabetic ketoacidosis, suspected diabetic ketoacidosis, hyperglycemic hyperosmolar state, or lactic acidosis; chronic complications of diabetes leading to severe target organ damage requiring urgent treatment, such as acute cardiovascular and cerebrovascular diseases, renal insufficiency, severe vision loss due to retinal disease, intermittent claudication and ischemic symptoms due to peripheral vascular disease, diabetic foot); (7) Women who are pregnant or breastfeeding; (8) Drug users and substance abusers; (9) Patients who are mentally incapacitated or unable to understand the requirements for participating in the study, making cooperation difficult; (10) Those expected to have poor compliance, unwilling or unable to follow postoperative therapy and\u002For rehabilitation program instructions; (11) Other comorbid conditions that limit participation in the study, hinder compliance with follow-up, or affect the scientific integrity of the study; (12) Other conditions judged by the investigator to be unsuitable for inclusion.",{"count":588,"type":21},76,[90],"The ACL surgery robot features a preoperative navigation system that enhances the precision of bone tunnel placement. As the first dual-bundle reconstruction surgical robot developed in China, it integrates advanced technology to ensure accurate anatomical alignment. This multi-center study aims to evaluate the robot's effectiveness in improving surgical outcomes and reducing complications, demonstrating the potential of domestic innovations in orthopedic surgery. With its high accuracy in locating bone tunnel footprints, this robot represents a significant advancement in ACL reconstruction techniques.\n\nThe trial is designed as a randomized controlled trial (RCT) led by a prospective randomized cohort. The study is initiated by Tsinghua University's long-term professor, Yu Jiakuo, and the product has received China's Class III clinical registration certificate.",[592],"Anterior Cruciate Ligament Rupture",[594,595,596,597,598],"Anterior cruciate ligament rupture","ACL reconstruction","Surgical Navigation","Robotic Surgery","Bone Tunnel Footprint Localization Accuracy","2025-02-28",{"date":601,"type":36},"2025-03-05",{"date":603,"type":36},"2025-01-24",{"date":605,"type":21},"2029-01-24",{"name":42,"class":43},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":262,"sex":17,"minAge":614,"maxAge":4,"enrollmentInfo":615,"targetDuration":4,"studyType":88,"phases":617,"briefSummary":618,"conditions":619,"keywords":622,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":44},"100406032","internet-technology-based-life-style-and-care-intervention-for-risk-factors-of-non-communicable-diseasesncd-100406032","NCT04567121","Internet Technology Based Life-style and Care Intervention for Risk Factors of Non Communicable Diseases（NCD）","Internet Technology Based Life-style and Care Intervention for Risk Factors of Non Communicable Diseases（NCD）-a Randomized, Controlled Trial in Communities Following Up for 50 Years","Inclusion Criteria:\n\n* Men and women older than 25 years of age with two or more risk factors as follows, BMI≥24 or BMI≤18.5 kg\u002Fm2, smoking, active exercise less than 30 minutes every day, blood pressure higher than 130\u002F85 mmHg, dyslipidemia, fasting glucose higher than 6.1mmol\u002Fl, fatty liver.\n* Patients with hypertension, diabetes and ASCVD\n\nExclusion Criteria:\n\n* Patients had not signed the consent form\n* Patients with severe heart failure, hepatic failure, renal failure and malignant tumor.\n* Patients planing pregnancy","25 Years",{"count":616,"type":21},60000,[90],"This study aims to control risk factors of non communicable diseases by life style and care intervention based on internet technology, looking forward to improve cardiovascular and cerebrovascular complications, diabetes and all-cause death.",[620,621],"Lifestyle Intervention","Non Communicable Diseases",[623,624,621],"Internet Technology","lifestyle intervention","2025-02-09",{"date":627,"type":36},"2025-02-11",{"date":629,"type":36},"2018-01-01",{"date":631,"type":21},"2070-12-01",{"name":42,"class":43},""]